Joint Academy

Trate el dolor articular crónico desde casa

***Joint academy is currently available in the UK as a self-funded service or through invite to participate in the local NHS or employer pilot.

However, as we launch Joint Academy in the UK we are pleased to offer the first two weeks of your treatment free of charge, with no commitment to pay thereafter. Continued self-funded treatment is available at a discounted rate of only £40 per month.***

Joint Academy is a clinically-proven, digital treatment for chronic hip and knee pain. With the app, the treatment is available wherever and whenever.

JOINT ACADEMY INCLUDES

- A personal licensed physiotherapist

- An individualised exercise program

- Education and interactive lessons

- Progress tracking

Over 35,000 patients treated. 96 % would recommend the treatment program.

A CLINICALLY VALIDATED TREATMENT

Science and peer-reviewed, published studies show that Joint Academy’s patients reduce their pain, change their mind about having surgery, and quit analgesics medication.

- 85 % reduce their joint pain

- 54 % change their mind about having surgery

- 42 % quit analgesics medication

JOINT ACADEMY SUITS THOSE WHO

- Experience pain and/or stiffness in hip or knee

- Want unlimited access to a physiotherapist

- Wish to start treatment immediately, without waiting

- Would like to treat chronic joint pain from home

HOW IT WORKS

- Download the Joint Academy app

- Connect with a personal licensed physiotherapist

- Start your personalised treatment

- Keep track of your progress and reach your goals

FIRST-LINE TREATMENT FOR OSTEOARTHRITIS

According to international guidelines, osteoarthritis treatment should primarily consist of specific exercise and education about the disease (and weight control in cases deemed necessary). Everyone who has osteoarthritis should be offered this type of treatment. Joint Academy follows these recommendations to offer a digital first-line treatment for osteoarthritis to reduce joint pain and increase physical function.